AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04502758 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham MagVenture TMS Therapy System w/Theta Burst Stimulation
Description: During each session continuous theta burst stimulation (cTBS) in which 1800 pulses are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDPFC). The device consists of a magnetic stimulator, MagPro X100 and a magnetic coil used for MT determination, C-B70 and a treatment coil, the Cool-B70 A/P coil. The A/P version of the coil, contains both an active site (A) and a sham (P) site. The magnetic field on the sham site is significantly reduced, and is less than 5% of that of the active site.
Study NCT05519579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 12mg given intrathecally within 24 hours prior to blinatumomab administration
Study NCT05519579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab 28ug/day continuous infusion for 4 weeks
Study NCT05471648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 420 mg EG1206A EirGenix Pertuzumab in 14 mL Injection
Description: Healthy volunteers receive pertuzumab (EG1206A, 420 mg, single dose)
Study NCT05471648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perjeta (EU origin) 420 mg in 14 mL Injection
Description: Healthy volunteers receive pertuzumab (Perjeta (EU origin) 420 mg, single dose)
Study NCT05471648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perjeta (US origin) 420 mg in 14 mL Injection
Description: Healthy volunteers receive pertuzumab (Perjeta (US origin), 420 mg, single dose)
Study NCT04886882 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: solution containing 0.9 % sodium chlorine
Study NCT04886882 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham comparator
Description: vaseline, beeswax,polyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water
Study NCT04886882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental drug 1
Description: A cream containing 10 % MgSO4.vaseline, beeswaxpolyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water
Study NCT04886882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental drug 2
Description: A cream containing 10 % MgSO4.vaseline, beeswax,polyglyceryl-3 diisostearate, sorbitan caprylate, propandiol,benzoic acid, glycerin, water
Study NCT04886882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Centella asiatica
Description: A cream containing Centella asiatica
Study NCT04704518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate Ophthalmic 0.4%
Description: Topical ophthalmic administration of one drop of Lagricel® Ofteno PF QID.
Study NCT04704518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trehalose 3% / Sodium Hyaluronate Ophthalmic 0.15%
Description: Topical ophthalmic administration of one drop of Thealoz® Duo QID.
Study NCT04928820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT04928820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV
Study NCT04928820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06418555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A home rehabilitation program centered on exercise
Description: Establish a multidisciplinary team, with team members combining clinical experience, summarizing the best evidence as the basis, and using the theory of behavior change wheels as the framework, to preliminarily construct a home-based cardiac rehabilitation plan suitable for TAVR patients in China's national conditions. Conduct expert consultation using the Delphi method to form the final version of the home cardiac rehabilitation plan for TAVR patients.
Study NCT05305287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: An insulin sensitizer and anti-diabetic agent. Participants will be started on 15 mg/day, increased to 30 mg/day at week 2 and then to 45 mg/day at week 4.
Study NCT05305287 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for pioglitazone
Study NCT06580418 — intervention group
Intervention type: OTHER
Intervention: Additional biopsies and blood samples
Description: During the endoscopic procedure planned for IBD patients following standard clinical practice, the endoscopist will decide the number and location of additional biopsy samples (up to 8) collected for the study. Participation in this study also requires the removal of three additional blood samples.
Study NCT06462911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH) - Spanish/Espanol
Description: HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. The entire HOBSCOTCH program has been translated into Spanish for people with epilepsy who speak Spanish.
Study NCT06580405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KNP-1000 Apheresis System
Description: sFlt-1 is removed from the participants' plasma through treatment.
Study NCT06579924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Disposable mini-PCNL
Description: Mini-PCNL carried out using disposable scope
Study NCT06579924 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Re-usable mini-PCNL
Description: Mini-PCNL carried out using re-usable scope
Study NCT06374446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical Treatment
Description: This group in our study exercises 2 days a week, 2 repetitions a day, 3 sets of 15 repetitions for 6 weeks. Upper and lower extremity exercises are available, including shoulder flexion and abduction, hip and knee exercises. Active breathing cycle is used as breathing exercises. Active respiratory cycle; Includes breathing control, thoracic expansion exercises and huffing. These are done for 6 weeks, along with upper and lower extremity exercises. All evaluations are made at the beginning and end of the groups.
Study NCT06374446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Combined with Classical Treatment
Description: This group in our study exercises 2 days a week, 2 repetitions a day, 3 sets of 15 repetitions for 6 weeks. Upper and lower extremity exercises are available, including shoulder flexion and abduction, hip and knee exercises. Active breathing cycle is used as breathing exercises. Active respiratory cycle; Includes breathing control, thoracic expansion exercises and huffing. These are done for 6 weeks, along with upper and lower extremity exercises. In addition, individuals can take a 30-minute walk in the forest, do yoga, etc. with virtual reality glasses. Videos for relaxation will be shown. All evaluations will be made at the beginning and end of the groups.
Study NCT06374446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Individuals in this group are given 30-minute walks in the forest, yoga, etc. with virtual reality glasses, 2 days a week, 2 times a day for 6 weeks. Videos for relaxation will be shown. All evaluations will be made at the beginning and end of the groups.
Study NCT06374446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: This group will be given a handbook explaining the importance of exercise in individuals with long-term symptoms after Covid.
Study NCT05757492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHS-006 (anti-TIGIT)
Description: Arm A participants will receive CHS-006 administered via IV Q3W.
Study NCT05757492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: toripalimab (anti-PD-1)
Description: Arm B participants will receive toripalimab administered via IV Q3W.
Study NCT06072534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mivacurium Chloride
Description: emergence modified sequence intubation
Study NCT05860127 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral for Cognitive Stimulation Therapy
Description: Physician will review participant eligibility for CST treatment and offer referral based on clinical judgement
Study NCT05860127 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No change to Standard of Care
Description: Participants will not receive referral from a physician. They will continue with standard of care at their site.
Study NCT04905615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data-driven and teacher led school based strategies.
Description: The intervention is individualised to each school, depending on the teacher led strategies which are data-informed
Study NCT06140108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Each participant will receive empagliflozin 10mg daily for 3 months.
Study NCT06140108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MetFORMIN 500 Mg Oral Tablet
Description: Each participant will receive metformin 1000mg daily for 3 months.
Study NCT04721925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social media messaging
Description: A motivational interviewing-based intervention delivered via private health coaching on social media for 8 weeks.
Study NCT04610931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Enhanced Cognitive Behavioral Therapy (VR-CBT)
Description: Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups.~In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage.~Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups. Subjects in the Virtual Reality group will receive 6 weekly individual CBT sessions followed by 6 virtual therapy sessions. Virtual therapy consists of exposing the patient to 3D situations considered to cause a high risk of smoking relapse and aiming to reduce signal reactivity by extinction. At each session, a neutral exposure will be given at the beginning to facilitate immersion and emergence of the session with a duration determined according to the sensitivity of each patient. Exposure is stopped when the craving approaches the baseline level.
Study NCT04610931 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavior therapy
Description: Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups. In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage.~Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups.
Study NCT06525948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: rhTPO
Study NCT06525948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A
Description: cyclosporine A
Study NCT06525948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: cyclosporine A
Study NCT05727410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab, docetaxel, cisplatin Group
Description: Patients will be treated with nivolumab 360mg and plus docetaxel 60mg/m2 and cisplatin 60mg/m2 every 3 weeks for 3 cycles and will be evaluated for the operability. Patients with R0 resection will receive radiation 59.4 Gy in 27 fractions. Boost RT of 6.6 Gy in 3 fractions to tumor bed and/or gross tumor will be optional in patients who had R1-R2 resection. If tumors are regarded inoperable after neoadjuvant therapy (due to high risk of post-operative complication, or metastatic disease), they will be off from this study and receive the appropriate treatment, though they will be also included in the efficacy and safety analyses.
Study NCT05449964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCALING AND ROOT PLANING (SRP)in single sitting
Description: SCALING AND ROOT PLANING (SRP) IS THE PRIMARY COURSE OF NON-SURGICAL PERIODONTAL TREATMENT THAT INVOLVES REMOVAL OF SUPRA-GINGIVAL AND SUB-GINGIVAL BIOFILM AND CALCULUS FOLLOWED BY THOROUGH ROOT PLANING.
Study NCT05449964 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCALING AND ROOT PLANING (SRP)in two sittings
Description: SCALING AND ROOT PLANING (SRP) IS THE PRIMARY COURSE OF NON-SURGICAL PERIODONTAL TREATMENT THAT INVOLVES REMOVAL OF SUPRA-GINGIVAL AND SUB-GINGIVAL BIOFILM AND CALCULUS FOLLOWED BY THOROUGH ROOT PLANING.
Study NCT06509256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: work aims to evaluate the role of tranexamic acid in bleeding control in gynecomastia surgery
Study NCT06291610 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinical trial decision support intervention
Description: 1. a patient decision aid tailored to clinical trial participation~2. decision coaching consultations carried out by trained healthcare professionals.~3. a training program in decision coaching will be an integrated part of the intervention.
Study NCT05569746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INM004
Description: Two 4 mg/kg doses of INM004, 24 h (±2 h) apart, will be assessed. Each dose will be administered as an intravenous infusion during 50 min.
Study NCT05569746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SoC
Description: Standard of care
Study NCT06580847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Singing
Description: 12 week choir program consisting of 1.5 hours of in-person instruction per week.
Study NCT06580847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audiobook Club
Description: 12 week audiobook club program consisting of 1.5 hours of in-person discussion per week.
Study NCT04712006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64304500
Description: Participants will be administered with JNJ-64304500 SC (Dose 1 or 2) injection on Day 1.
Study NCT05379543 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: Echocardiography is performed using a GE Vingmed Ultrasound System (GE Healthcare, Horten, Norway), by an experienced expert. Morphological and functional parameters of the heart are measured in a consistent manner.
Study NCT04547374 — intervention group
Intervention type: OTHER
Intervention: GaH Intervention
Description: Patients in this cohort will be referred for management/intervention with GaH.~However, the purpose of this program is not to define, control, or evaluate the specific details of the GaH process or procedure, but to evaluate its effectiveness as an alternative clinical care path in this setting. As such, the specific details and actions of the GaH care team in each patient interaction are left to their medical discretion.
Study NCT05263466 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: For the diagnostic imaging aspect included in this pilot study, \[68Ga\]PSMA-11 will be used. This is a peptidomimetic agent with a covalently bound chelator (HBED-CC) that is FDA-approved in prostate cancer imaging. We will use PET-MRI to visualise a) the concentration and b) the distribution of this tracer to establish a functional map of primary brain tumour activity
Study NCT05263466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain tumour biopsy
Description: All patients included in our study will undergo stereotactic surgery for biopsy/resection of the tumour as part of the standard of care at KCH. During this study we will not vary from the surgical standard of care for primary brain tumours and will only extend the surgery time due to additional stereotactic biopsies (an additional 3 biopsies increasing the time of the operation by \~30 minutes). Professor Ashkan (KCH) has defined the additional surgical risk of performing these biopsies to be \~0%, since targeted biopsies will only be taken within the tumour just before resection. The stereotactic biopsy may be targeted to areas of high \[68Ga\]PSMA SUV within the tumour as defined by the PET MRI scan.
Study NCT05203484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multielecotrde Mapping
Description: Multielectrode Mapping with Pentaray/Octaray
Study NCT05203484 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Point-by-point mapping
Description: Point-by-point mapping with QDot
Study NCT05204589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aerosolized Ad5-nCoV
Description: Aerosolized Ad5-nCoV is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.1 ml / dose, contains 1×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
Study NCT06577545 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioural Lifestyle (BL)
Description: 24-week behavioural lifestyle intervention
Study NCT05204589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccine
Description: Inactivated SARS-CoV-2 vaccine is homologous to the priming series which have been administered to the subjects, produced by SinoVac Biotech Co,. Ltd, Beijing Institute of Biological Products Co,. Ltd, Wuhan Institute of Biological Products Co,. Ltd, or Biokangtai.
Study NCT05038280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Talk about Children intervention
Description: The LTC -intervention includes two steps: Let´s Talk about Children discussion and Let´s Talk about Children network meeting. Students, students´ parents, and a teacher take part in the LTC -discussion. The LTC logbook is used as the framework for the discussions. The LTC discussion depicts the child's ordinary day in all developmental contexts and an action plan is made with parents to enhance the identified strengths and to give support in vulnerabilities. When the action plan is difficult to carry out without further participants, the LTC-Network meeting is planned with parents (and sometimes also the child). LTC-Network meeting provides a forum for case-based cross-sectoral collaboration, including also the families and their social network.
Study NCT04792697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increase morning bright light
Description: Participants will wear Re-Timer bright glasses for 30 minutes each morning upon rising
Study NCT04792697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decrease evening blue light
Description: Participants will wear blue light blocker goggles for 2 hours before bed
Study NCT04792697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Scheduling
Description: Participants will advance their bedtime by 1.5 hours and regularize their wake time
Study NCT04792697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitor sleep, mood, and substance use
Description: Participants will complete smartphone-based sleep, mood, and substance use monitoring
Study NCT04792697 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitor sleep, mood, and substance use
Description: Participants will complete smartphone-based sleep, mood, and substance use monitoring
Study NCT04732091 — intervention group
Intervention type: PROCEDURE
Intervention: Therapeutic ultrasound with 20 usec
Description: A custom designed high mechanical index (MI) impulses at 4-20 usec and >1.0 mechanical index designed for the 1.8 MHz S5-1 transducer
Study NCT05934812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: 24IU oxytocin liquid delivered with a pump-actuated nasal spray device, administered twice-daily
Study NCT05934812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo liquid nasal spray administered twice-daily
Study NCT04851483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2328065
Description: Solid Form, Oral administration.
Study NCT04851483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo of BAY2328065.
Study NCT06577883 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Chest X-ray Tomosynthesis
Description: An imaging device that uses X-rays projected from multiple angles to reconstruct a three-dimensional images of the chest
Study NCT06576388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXG001-307 injection
Description: Research process includes filter (subjects signed informed consent for screening period before the pretreatment to the hormone, the longest 28 days), treatment period (the subjects accept including single hormone pretreatment, the study drug infusion) hospitalization and observation and follow-up treatment period (subjects to the participants to 18 months, lost to follow-up, active exit research subjects, or death). Subjects qualified in the screening period entered the treatment period and received EXG001-307, and entered the follow-up period after hospitalization. At the end of the study visit (subject at 18 months of age), eligible subjects will be asked to transfer to the long-term follow-up study.